# UCB BIOSCIENCES, Inc. clinical trials: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with UCB BIOSCIENCES, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by UCB BIOSCIENCES, Inc.: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ucb-biosciences-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 31, 2026 | NCT07503444 | A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome | UCB BIOSCIENCES, Inc. | Phase 3 | Recruiting | Rett Syndrome | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503444) |
| November 7, 2024 | NCT06679413 | A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants | UCB BIOSCIENCES, Inc. | Phase 1 | Completed | Healthy Study Participants | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06679413) |
| September 19, 2024 | NCT06590493 | Doxecitine and Doxribtimine-Expanded Access | UCB BIOSCIENCES, Inc. | Not applicable | Available | Thymine Kinase 2 Deficiency | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06590493) |
| November 7, 2023 | NCT06118255 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of... | UCB BIOSCIENCES, Inc. | Phase 3 | Completed | Dravet Syndrome | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06118255) |
| February 19, 2019 | NCT03845712 | An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Thymidine Kinase 2 Deficiency | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03845712) |
| June 20, 2016 | NCT02806219 | Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device... | UCB BIOSCIENCES, Inc. | Phase 1 | Completed | Healthy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02806219) |
| May 17, 2016 | NCT02775656 | UCB Cimzia Pregnancy Follow-up Study | UCB BIOSCIENCES, Inc. | Observational | Terminated | Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing... | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02775656) |
| March 17, 2016 | NCT02710890 | Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. | UCB BIOSCIENCES, Inc. | Phase 2/3 | Completed | Epilepsy | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02710890) |
| June 23, 2015 | NCT02477839 | Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to \<4 Years With Partial-onset Seizures | UCB BIOSCIENCES, Inc. | Phase 3 | Completed | Epilepsy With Partial-onset Seizures | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02477839) |
| April 3, 2015 | NCT02408549 | Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures | UCB BIOSCIENCES, Inc. | Phase 3 | Completed | Epilepsy | 239 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02408549) |
| April 3, 2015 | NCT02408523 | A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic... | UCB BIOSCIENCES, Inc. | Phase 3 | Completed | Epilepsy | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02408523) |
| June 3, 2014 | NCT02154425 | A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers | UCB BIOSCIENCES, Inc. | Phase 1 | Completed | Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic... | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02154425) |
| March 17, 2014 | NCT02088957 | Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures | UCB BIOSCIENCES, Inc. | Phase 2 | Terminated | Nonconvulsive Electrographic Seizures | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02088957) |
| December 24, 2013 | NCT02019602 | A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta | UCB BIOSCIENCES, Inc. | Phase 1 | Completed | Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02019602) |
| October 17, 2013 | NCT01964560 | A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset... | UCB BIOSCIENCES, Inc. | Phase 3 | Completed | Epilepsy | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01964560) |
| February 15, 2012 | NCT01533714 | The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis | UCB BIOSCIENCES, Inc. | Phase 2 | Terminated | Rheumatoid Arthritis | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01533714) |
| December 23, 2011 | NCT01498120 | Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Restless Legs Syndrome | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01498120) |
| December 20, 2011 | NCT01495793 | Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Restless Legs Syndrome | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01495793) |
| April 20, 2011 | NCT01339559 | Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy | UCB BIOSCIENCES, Inc. | Phase 3 | Completed | Epilepsy | 767 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01339559) |
| February 15, 2011 | NCT01296711 | Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 | UCB BIOSCIENCES, Inc. | Phase 2 | Terminated | Rheumatoid Arthritis | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01296711) |
| May 7, 2010 | NCT01118962 | Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic... | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Epilepsy | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01118962) |
| May 7, 2010 | NCT01118949 | Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Epilepsy | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01118949) |
| August 19, 2009 | NCT00961441 | Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Epilepsy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00961441) |
| July 14, 2009 | NCT00938912 | An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy | UCB BIOSCIENCES, Inc. | Phase 2 | Completed | Epilepsy | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00938912) |
| February 16, 2009 | NCT00844285 | SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry | UCB BIOSCIENCES, Inc. | Observational | Completed | Crohn's Disease | 3,072 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00844285) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |
| Not applicable | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Terminated | 4 |
| Available | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 13 |
| Seizures | 6 |
| Arthritis, Rheumatoid | 5 |
| Epilepsy, Idiopathic Generalized | 4 |
| Crohn Disease | 4 |
| Epilepsies, Partial | 3 |
| Arthritis, Psoriatic | 3 |
| Axial Spondyloarthritis | 3 |
| Spondylitis, Ankylosing | 3 |
| Autoimmune Diseases | 3 |
| Restless Legs Syndrome | 2 |
| Congenital Abnormalities | 1 |
| Mitochondrial Diseases | 1 |
| Muscle Weakness | 1 |
| Muscular Atrophy | 1 |
| Epilepsies, Myoclonic | 1 |
| Rett Syndrome | 1 |
| Breast Feeding | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
